Literature DB >> 11241133

Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration.

P L Faries1, D I Rohan, H Takahara, M C Wyers, M A Contreras, W C Quist, G L King, F W Logerfo.   

Abstract

PURPOSE: Patients with diabetes mellitus (DM) experience progressive macrovascular atherosclerosis and intimal hyperplastic restenosis with increased frequency as compared with nondiabetic patients. These observations suggest that vascular smooth muscle cells (VSMCs) behave in a phenotypically different and more aggressive manner in diabetic patients. In this study, we compared the in vitro rates of proliferation, adhesion, and migration of human VSMCs obtained from diabetic and nondiabetic patients.
METHODS: Human VSMC cultures were isolated from 23 diabetic patients (9 artery, 14 vein) and 15 nondiabetic patients (9 artery, 6 vein) with extensive lower extremity atherosclerosis. All patients were between 61 and 78 years of age (average: 68.4 years [diabetic]; 67.3 years [nondiabetic]). All diabetic patients had type 2 DM. Vascular specimens were obtained at the time of amputation from infragenicular arteries and during arterial revascularization from saphenous veins. Cells from passages 2 and 3 were assayed for their proliferative capacity with total DNA fluorescence photometry and for adhesion and migration with a modified Boyden chamber.
RESULTS: The average duration of diabetes was 11.6 +/- 4.1 years. The average number of diabetic complications (retinopathy, neuropathy, nephropathy, coronary artery disease) was 2.8 +/- 0.7 per patient. Diabetic VSMCs exhibited abnormal morphology in cell culture with loss of the normal hill and valley configuration. Proliferation was significantly increased in VSMCs of diabetic origin (156 +/- 57 absorption units) as compared with those of nondiabetic origin (116 +/- 42 absorption units) (P <.001). Diabetic VSMCs demonstrated significantly greater adhesion (63.6 +/- 24 per high-power field vs 37.9 +/- 13 per high-power field; P =.002) and migration (397 +/- 151 per low-power field vs 121 +/- 99 per low-power field; P =.001) rates.
CONCLUSIONS: Diabetic VSMCs exhibit significantly increased rates of proliferation, adhesion, and migration as well as abnormal cell culture morphology suggestive of abnormal contact inhibition. These observations of human VSMCs in culture are consistent with the increased rate of infragenicular atherosclerosis and the increased rates of restenosis observed clinically in diabetic patients. The atherosclerosis- and intimal hyperplasia-promoting behavior exhibited appears to be intrinsic to the DM-VSMC phenotype and must be considered when designing methods to limit atherosclerosis and intimal hyperplasia in diabetic patients.

Entities:  

Mesh:

Year:  2001        PMID: 11241133     DOI: 10.1067/mva.2001.111806

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  31 in total

Review 1.  Vascular Smooth Muscle as a Target for Novel Therapeutics.

Authors:  Karen E Porter; Kirsten Riches
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

2.  Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats.

Authors:  Chris J Sullivan; Thomas H Teal; Ian P Luttrell; Khoa B Tran; Mette A Peters; Hunter Wessells
Journal:  Physiol Genomics       Date:  2005-08-23       Impact factor: 3.107

3.  Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus.

Authors:  Daniel J Lightell; Stephanie C Moss; T Cooper Woods
Journal:  Atherosclerosis       Date:  2017-12-09       Impact factor: 5.162

4.  A cautionary tale for autologous vascular tissue engineering: impact of human demographics on the ability of adipose-derived mesenchymal stem cells to recruit and differentiate into smooth muscle cells.

Authors:  Jeffrey T Krawiec; Justin S Weinbaum; Claudette M St Croix; Julie A Phillippi; Simon C Watkins; J Peter Rubin; David A Vorp
Journal:  Tissue Eng Part A       Date:  2014-09-16       Impact factor: 3.845

5.  Functional constituents of a local serotonergic system, intrinsic to the human coronary artery smooth muscle cells.

Authors:  Kannan Baskar; Swastika Sur; Vithyalakshmi Selvaraj; Devendra K Agrawal
Journal:  Mol Biol Rep       Date:  2015-04-11       Impact factor: 2.316

6.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

7.  Intracellular Ca2+ regulating proteins in vascular smooth muscle cells are altered with type 1 diabetes due to the direct effects of hyperglycemia.

Authors:  Yvonne M Searls; Rajprasad Loganathan; Irina V Smirnova; Lisa Stehno-Bittel
Journal:  Cardiovasc Diabetol       Date:  2010-02-01       Impact factor: 9.951

8.  Gas6-axl receptor signaling is regulated by glucose in vascular smooth muscle cells.

Authors:  Megan E Cavet; Elaine M Smolock; Oktay H Ozturk; Cameron World; Jinjiang Pang; Atsushi Konishi; Bradford C Berk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-21       Impact factor: 8.311

9.  Anti-atherogenic effect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro.

Authors:  Rituparna Ganguly; Amy M Wen; Ashley B Myer; Tori Czech; Soumyadip Sahu; Nicole F Steinmetz; Priya Raman
Journal:  Nanoscale       Date:  2016-03-28       Impact factor: 7.790

Review 10.  The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus.

Authors:  Chris P H Lexis; Braim M Rahel; Joan G Meeder; Felix Zijlstra; Iwan C C van der Horst
Journal:  Cardiovasc Diabetol       Date:  2009-07-28       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.